Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial ResultsPRNewsWire • 05/09/24
Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024PRNewsWire • 04/08/24
Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024PRNewsWire • 03/05/24
Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial ResultsPRNewsWire • 02/27/24
Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid TumorsPRNewsWire • 02/12/24
Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferencePRNewsWire • 02/01/24
Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated MilestonesPRNewsWire • 01/08/24
Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial ResultsPRNewsWire • 11/14/23
Nuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology DayPRNewsWire • 11/01/23
Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLCPRNewsWire • 10/13/23
Preliminary Phase 1 Dose-Escalation Data from ALKOVE-1 Trial of NVL-655 Demonstrated Activity in Heavily Pre-Treated Patients with ALK-Positive NSCLC and an ALK-Selective, TRK-Sparing Safety ProfilePRNewsWire • 10/04/23